What is Vaxcyte?
Vaxcyte operates at the vanguard of vaccine technology, focusing on the discovery and development of novel, high-efficacy vaccines designed to prevent and treat some of the most prevalent and lethal infectious diseases worldwide. By leveraging advanced scientific methodologies, the company aims to overcome the limitations of traditional vaccine platforms. Its market position is fortified by a sophisticated pipeline and a strategic focus on high-unmet-need therapeutic areas, positioning it as a critical player in the global health landscape. The company's ability to attract top-tier life sciences investors highlights its potential to disrupt the current vaccine market through superior clinical outcomes and innovative research and development strategies.
How much funding has Vaxcyte raised?
Vaxcyte has raised a total of $1.1B across 7 funding rounds:
Series A
$22M
Series B
$60M
Other Financing Round
$4M
Series C
$85M
Series D
$110M
Stock Offering
$100M
Share Placement
$750M
Series A (2015): $22M with participation from Abingworth, Longitude Capital, Roche, and CTI Life Sciences Fund
Series B (2017): $60M led by CTI Life Sciences Fund, Pivotal Bioventure Partners, Abingworth, Frazier Healthcare Partners, Longitude Capital, and Roche
Other Financing Round (2017): $4M supported by CTI Life Sciences Fund, Abingworth, Longitude Capital, and Roche
Series C (2018): $85M, investors not publicly disclosed
Series D (2020): $110M backed by Medixc, Janus Henderson Investors, Abingworth LLP, Pivotal Bioventure Partners, RA Capital Management , LLC, Texas Pacific Group, Foresite Capital, Frazier Health Care Partners, CTI Life Sciences, Longitude Capital, and Roche
Stock Issuance/Offering (2022): $100M, investors not publicly disclosed
Share Placement (2024): $750M, investors not publicly disclosed
Key Investors in Vaxcyte
Roche
A global pioneer in pharmaceuticals and diagnostics, Roche is dedicated to advancing science to improve lives through innovative healthcare solutions and personalized medicine.
Abingworth
A leading transatlantic life sciences investment firm that provides capital and expertise to top-tier management teams building world-class biotech companies.
Longitude Capital
A healthcare-focused venture capital firm that invests in biotechnology and medical technology, pairing sector expertise with flexible capital to help innovators scale.
What's next for Vaxcyte?
Following the recent infusion of capital, Vaxcyte is well-positioned to accelerate its clinical development programs and expand its research capabilities. The company is expected to prioritize the advancement of its lead candidates through late-stage clinical trials, while simultaneously scaling its operational infrastructure to support future commercialization efforts. Given the current enterprise-level funding context, the firm will likely focus on strengthening its intellectual property portfolio and fostering strategic partnerships to enhance its competitive edge. As Vaxcyte transitions into its next phase of growth, the focus will remain on delivering transformative medical solutions that address critical gaps in infectious disease prevention, ultimately aiming to improve patient outcomes on a global scale.
See full Vaxcyte company page
